Заболеваемость неалкогольной жировой болезнью печени в Гонконге: популяционное исследование с применением серийной протонной магнитно-резонансной спектроскопии
Vincent Wai-Sun Wong1,2,3, Grace Lai-Hung Wong1,2,3, David Ka-Wai Yeung4, Tina Kit-Ting Lau1,2,3, Carmen Ka-Man Chan1,2,3, Angel Mei-Ling Chim1,2,3, Jill M. Abrigo5, Ruth Suk-Mei Chan3,6, Jean Woo3,6, Yee-Kit Tse1,2,3, Winnie Chiu-Wing1,5,*, Chu Henry Lik-Yuen Chan1,2,3,*
1 Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China;2 State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; 3 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; 4 Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China; 5 Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong, China; 6 Centre for Nutritional Studies, The Chinese University of Hong Kong, Hong Kong, China
См.
Пентоксифиллин и кортикостероиды в лечении тяжелого алкогольного гепатита: открытое рандомизированное сравнительное исследование
Seung Ha Park1, Dong Joon Kim2,*, Young Seok Kim3, Hyung Joon Yim4, Won Young Tak5, Heon Ju Lee6, Joo Hyun Sohn7, Ki Tae Yoon8, In Hee Kim9, Hyoung Su Kim10, Soon Ho Um11, Soon Koo Baik12, June Sung Lee13, Ki Tae Suk2, Sang Gyune Kim3, Sang Jun Suh4, Soo Young Park5,Tae Yeob Kim7, Jae Young Jang14, от имени исследовательской группы по заболеваниям, связанным со злоупотреблением алкоголем при Корейской ассоциации по изучению заболеваний печени
1 Department of Internal Medicine, Inje University Haeundae Paik-Hospital, Inje University College of Medicine, Busan, Republic of Korea; 2 Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea; 3 Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea; 4 Department of Internal Medicine, Korea University College of Medicine, Ansan, Republic of Korea; 5 Department of Internal Medicine, Kyungpook National University College of Medicine, Daegu, Republic of Korea; 6 Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea; 7 Department of Internal Medicine, Hanyang University College of Medicine, Guri, Republic of Korea; 8 Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea; 9 Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea; 10 Department of Internal Medicine, Hallym University College of Medicine, Seoul, Republic of Korea; 11 Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea; 12 Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea; 13 Department of Internal Medicine, Inje University College of Medicine, Goyang, Republic of Korea; 14 Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Republic of Korea
См.
Двухкомпонентная терапия даклатасвиром и асунапревиром у пациентов, инфицированных вирусом гепатита C генотипа 1b, с ограниченными возможностями лечения
Yoshiyuki Suzuki1,*, Kenji Ikeda1, Fumitaka Suzuki1, Joji Toyota2, Yoshiyasu Karino2, Kazuaki Chayama3, Yoshiiku Kawakami3, Hiroki Ishikawa4, Hideaki Watanabe4, Wenhua Hu5, Timothy Eley6, Fiona McPhee5, Eric Hughes7, Hiromitsu Kumada1
1 Department of Hepatology, Toranomon Hospital, Tokyo, Japan; 2 Department of Hepatology, Sapporo Kosei General Hospital, Sapporo, Japan; 3 Department of Medicine and Molecular Science, Hiroshima University, Hiroshima, Japan; 4Bristol-Myers KK, Tokyo, Japan; 5Bristol-Myers Squibb Research and Development, Wallingford, CT, USA; 6 Bristol-Myers Squibb Research and Development, Hopewell, NJ, USA; 7 Bristol-Myers Squibb Research and Development, Princeton, NJ, USA
Актуальность и цели.
Рандомизированное исследование даклатасвира и асунапревира в сочетании с пэгинтерфероном и рибавирином или без них у пациентов, инфицированных вирусом гепатита C генотипа 1, с нулевым ответом на предшествующее лечение
Anna S. Lok1,*, David F. Gardiner2, Christophe Hezode3, Eric J. Lawitz4, Marc Bourliere5, Gregory T. Everson6, Patrick Marcellin7, Maribel Rodriguez-Torres8, Stanislas Pol9, Lawrence Serfaty10, Timothy Eley2, Shu-Pang Huang11, Jianling Li11, Megan Wind-Rotolo11, Fei Yu12, Fiona McPhee12, Dennis M.
Симепревир в сочетании с пэгинтерфероном и рибавирином у нелеченных пациентов с гепатитом С, вызванным вирусом генотипа 1, в японском исследовании III фазы CONCERTO-1
Norio Hayashi1, Namiki Izumi2, Hiromitsu Kumada3, Takeshi Okanoue4, Hirohito Tsubouchi5, Hiroshi Yatsuhashi6, Mai Kato7, Rito Ki7, Yuji Komada7, Chiharu Seto7, Shoichiro Goto7,*
1 Kansai Rosai Hospital, Hyogo, Japan; 2 Musashino Red-Cross Hospital, Tokyo, Japan; 3 Toranomon Hospital, Tokyo, Japan; 4 Saiseikai Suita Hospital, Osaka, Japan; 5 Kagoshima University Medical and Dental Hospital, Kagoshima, Japan; 6 National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan; 7 Research & Development, Janssen Pharmaceutical K.K., Tokyo, Japan
Актуальность и цели.
Количественное определение HBsAg у больных хроническим гепатитом B, ранее не получавших аналогов нуклеотидов (нуклеозидов), которым было назначено лечение энтекавиром с тенофовиром или без него в исследовании BE-LOW
Fabien Zoulim1,*, Giampiero Carosi2, Susan Greenbloom3, Wlodzimierz Mazur4, Tuan Nguyen5, Lennox Jeffers6, Maurizia Brunetto7, Song Yu8, Cyril Llamoso8
1 Hepatology Department, Hospices Civils de Lyon, INSERM U1052, Lyon University, Lyon, France; 2 University of Brescia, Brescia, Italy; 3 Toronto Digestive Disease Associates, Inc., Toronto, Canada; 4 Silesian Medical University, Katowice, Poland; 5 Alvarado Hospital Medical Center, San Diego, CA, USA; 6 University of Miami, Miller School of Medicine, Miami, FL, USA; 7 Liver Unit, University Hospital Pisa, Pisa, Italy; 8 Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA
Актуальность и цели.
Преднизолон vs пентоксифиллин при тяжелом алкогольном гепатите
Alexandre Louvet*
Hopital Huriez, Service des maladies de l’appareil digestif, Lille, France; INSERM 995, Lille, France
См. статью Park et al.
Развитие и ремиссия неалкогольной жировой болезни печени: только ли масса тела имеет значение?
Giulio Marchesini*, Arianna Mazzotti
Unit of Metabolic Diseases & Clinical Dietetics, “Alma Mater Studiorum” University, Bologna, Italy
См. статью Wong et al.
Статины — средство на все случаи жизни?
Francesco Negro*
Division of Gastroenterology and Hepatology, University Hospitals, Geneva, Switzerland; Division of Clinical Pathology,University Hospitals, Geneva, Switzerland
См. статью Simon et al.